First posted October, 2021, Updated January, 2022; Recruiting
The purpose of this Phase 2a PREVAIL-2 trial is to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) patients with active disease after amelioration induced by corticosteroid treatment.
To Learn More Contact
Clinical Operations at 857-675-1664 or email email@example.com
Chief Medical Officer at 908-356-0514 or email firstname.lastname@example.org
ClinicalTrials.gov identifier (NCT number): NCT05087628